Physician profile
Catherine E Easterwood
NPI 1902249394
$2,292.86
in general payments reported to CMS, 2019-2025
16 companies · $35.46 in 2025
The $35.46 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $685 · 2022: $1,190 · 2023: $383 · 2025: $35.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $395.36 | 2021-2023 | Arikayce |
| Abbvie INC. | $365.14 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $322.65 | 2021-2023 | Dificid, Recarbrio, Zerbaxa |
| Cumberland Pharmaceuticals, INC. | $223.94 | 2021-2022 | |
| Theratechnologies INC. | $196.31 | 2021-2023 | Egrifta, Trogarzo |
| Astellas Pharma US INC | $164.84 | 2022-2023 | Cresemba |
| Viiv Healthcare Company | $151.00 | 2021-2022 | |
| Gilead Sciences, INC. | $149.43 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $119.13 | 2021-2023 | Xerava |
| Melinta Therapeutics, LLC | $64.34 | 2022-2023 | Kimyrsa, Vabomere |
| Abiomed | $35.46 | 2025 | |
| Janssen Biotech, INC. | $29.33 | 2022 | |
| Ferring Pharmaceuticals INC. | $25.62 | 2023 | Rebyota |
| Grifols USA, LLC | $20.39 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.95 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Easterwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.